HCPCS J-Codes
Drugs administered other than oral method, chemotherapy drugs

These codes are used to report injectable drugs that ordinarily cannot be self-administered; chemotherapy, immunosuppressive drugs and inhalation solutions as well as some orally administered drugs.

View All HCPCS Sections

  • J9341

    Injection, thiotepa (tepylute), 1 mg

  • J9342

    Injection, thiotepa, not otherwise specified, 1 mg

  • J9345

    Injection, retifanlimab-dlwr, 1 mg

  • J9347

    Injection, tremelimumab-actl, 1 mg

  • J9348

    Injection, naxitamab-gqgk, 1 mg

  • J9349

    Injection, tafasitamab-cxix, 2 mg

  • J9350

    Injection, mosunetuzumab-axgb, 1 mg

  • J9351

    Injection, topotecan, 0.1 mg

  • J9352

    Injection, trabectedin, 0.1 mg

  • J9353

    Injection, margetuximab-cmkb, 5 mg

  • J9354

    Injection, ado-trastuzumab emtansine, 1 mg

  • J9355

    Injection, trastuzumab, excludes biosimilar, 10 mg

  • J9356

    Injection, trastuzumab, 10 mg and hyaluronidase-oysk

  • J9357

    Injection, valrubicin, intravesical, 200 mg

  • J9358

    Injection, fam-trastuzumab deruxtecan-nxki, 1 mg

  • J9359

    Injection, loncastuximab tesirine-lpyl, 0.075 mg

  • J9360

    Injection, vinblastine sulfate, 1 mg

  • J9361

    Injection, efbemalenograstim alfa-vuxw, 0.5 mg

  • J9370

    Vincristine sulfate, 1 mg

  • J9371

    Injection, vincristine sulfate liposome, 1 mg

  • J9376

    Injection, pozelimab-bbfg, 1 mg

  • J9380

    Injection, teclistamab-cqyv, 0.5 mg

  • J9381

    Injection, teplizumab-mzwv, 5 mcg

  • J9382

    Injection, zenocutuzumab-zbco, 1 mg

  • J9390

    Injection, vinorelbine tartrate, 10 mg

  • J9393

    Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg

  • J9394

    Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg

  • J9395

    Injection, fulvestrant, 25 mg

  • J9400

    Injection, ziv-aflibercept, 1 mg

  • J9600

    Injection, porfimer sodium, 75 mg

  • J9601

    Injection, linvoseltamab-gcpt, 1 mg

  • J9999

    Not otherwise classified, antineoplastic drugs

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 7/22/2026

CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.